PURPOSE: To examine the effectiveness of two methods of preventing blister formation under the taped portion of postoperative hip surgical dressings. DESIGN: Comparative intervention study. SAMPLE: Convenience sample of 148 consecutive hip surgery patients in two Connecticut community hospitals. METHODS: Patients were preoperatively assigned to one of two postoperative surgical hip dressing taping methods or to the control group. The experimental group had the surgical dressing taped to either a hydrocolloid barrier or a nonhydrocolloid barrier 1-inch circumferentially around the surgical incision with the control group having the dressing taped directly to the skin. FINDINGS: The research results found that taping the surgical dressing to a hydrocolloid barrier prevented blister formation. There were no blisters in either experimental group, but evidence of nonblanchable erythema on two patients in the nonhydrocolloid barrier group. CONCLUSION: Taping of postoperative surgical hip dressings to a hydrocolloid barrier is superior to taping directly to skin or to a nonhydrocolloid barrier. IMPLICATIONS FOR NURSING RESEARCH: A larger scale study to examine potential factors that might place patients at high risk for blister formation is needed. This would aid in identification of patients that would benefit from different surgical dressing taping methods.

Adhesives↗

PubMedDate not supplied

Get ready for action this winter.

Explore the source record for details and available documents.

Attitude of Health Personnel↗

PubMedDate not supplied

The influencer.

Explore the source record for details and available documents.

Humans↗

PubMedDate not supplied

Hess' sign produced by bedrail injury.

Explore the source record for details and available documents.

Aged↗

PubMedDate not supplied

Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the hand.

OBJECTIVE: This multicentre, randomized, double-blind, placebo-controlled parallel-group study was undertaken to investigate the efficacy, safety and tolerability of lumiracoxib (Prexige), a cyclooxygenase-2 selective inhibitor, in patients with primary osteoarthritis (OA) of the hand. METHODS: The study randomized 594 patients aged > or = 18 years with symptomatic OA of the hand. Patients underwent a 3 to 7-day washout for previous nonsteroidal anti-inflammatory drugs and those with pain intensity > or = 40 mm on a 100 mm Visual Analogue Scale (VAS) in the target hand during the 24 hours prior to baseline and an increase in pain intensity of either > or = 20% or > or = 10 mm VAS since screening (whichever was greater) were randomized to lumiracoxib 200 mg once daily (od) (n=205), lumiracoxib 400 mg od (n=193) or placebo (n=196). The primary efficacy variable was overall OA pain intensity (VAS mm) in the target hand after 4 weeks of treatment. Safety and tolerability assessments were performed. RESULTS: After 4 weeks of treatment, overall OA pain intensity in the target hand was significantly lower for patients treated with lumiracoxib compared with patients treated with placebo (both doses p<0.001). There was no significant difference between lumiracoxib doses in terms of the reduction in overall OA pain intensity. Lumiracoxib was well tolerated. The incidence of adverse events was similar for active treatment groups and placebo. CONCLUSIONS: Lumiracoxib 200 and 400 mg od were effective and well tolerated treatments for OA of the hand. Lumiracoxib significantly improved overall OA pain intensity in the target hand versus placebo, with a tolerability profile similar to placebo.

Aged↗